Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
BA-3071 by BioAtla for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval
BA-3071 is under clinical development by BioAtla and currently in Phase II for Gastroesophageal (GE) Junction Carcinomas. According to GlobalData,...
Data Insights
BA-3071 by BioAtla for Uveal Melanoma: Likelihood of Approval
BA-3071 is under clinical development by BioAtla and currently in Phase II for Uveal Melanoma. According to GlobalData, Phase II...